Live Breaking News & Updates on Allogeneic Stem Cell Transplantation

Stay updated with breaking news from Allogeneic stem cell transplantation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that the Company is expected to be added to the. | May 22, 2023 ....

City Of , United Kingdom , United States , Brianm Culley , London Stock Exchange Group , Roche Group , Lineage Cell Therapeutics Inc , Lineage Cell Therapeutics , London Stock Exchange , Cell Therapeutics , Nc Stock Exchange , Press Release , O Lctx Us53566p1093 ,

Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional

Hypoimmune-modified allogeneic iPSCs evade immune response and rejection without immunosuppression in non-human primate model Long-term survival and immune evasion of hypoimmune-modified allogeneic. | May 8, 2023 ....

United Kingdom , Doug Williams , Company Securities , Sana Biotechnology Inc , Exchange Commission , Nature Biotechnology , Avoid Immune Activation , Escape Systemic Immune Rejection , All Three Germ Layers , Collectively Avoiding Immune Recognition , Islet Cells Survive , Provided Widespread Protection Against , Innate Immune Response , South San Francisco , Sana Biotechnology , Quarterly Report , Nc Stock Exchange , Press Release , F Sana Us7995661045 ,

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences, Inc. , a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on April 27, 2023,. | May 8, 2023 ....

Compensation Committee Of Precision Board Directors , Precision Biosciences Inc , Precision Biosciences , Compensation Committee , Inducement Incentive Award Plan , Nasdaq Listing Rule , Common Stock , Nc Stock Exchange , Press Release , Pril Dtil Us74019p1084 ,

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

Enrollment Ongoing in Industry’s First Potentially Pivotal Phase 2 Allogeneic CAR T Trial, ALPHA2, in Relapsed/Refractory Large B Cell LymphomaInitiated Phase 2 EXPAND Trial to Support Licensure. | May 3, 2023 ....

United States , David Chang , Christine Cassiano , Allogene Allo , Timothy Moore , American Association Of Cancer Research , Drug Administration , American Association For Cancer Research , Allocart Program , Allogene Therapeutics Inc , American Society Of Clinical Oncology , Enrollment Ongoing , First Potentially Pivotal Phase , Refractory Largeb Cell , Support Licensure , Lymphodepleting Agent , American Society , Clinical Oncology , Annual Meeting Presentation , Interim Phase , Renal Cell Carcinoma , American Association , Cancer Research , Annual Meeting , Provide Proof Of Concept , Partial Response Following ,

AlloVir to Present at the BofA Securities 2023 Health Care Conference

AlloVir, Inc. , a late-clinical stage allogeneic T cell immunotherapy company, announced today that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the BofA. | May 1, 2023 ....

Las Vegas , United States , Diana Brainard , Allovir Inc , Health Care Conference In Las Vegas , Chief Executive Officer , Bofa Securities , Care Conference , Nc Stock Exchange , Press Release , He Alvr Us0198181036 ,